Recombinant Anti-LRP6 antibody [EPR2423(2)] (ab134146)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2423(2)] to LRP6
- Suitable for: WB
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Product nameAnti-LRP6 antibody [EPR2423(2)]
See all LRP6 primary antibodies
DescriptionRabbit monoclonal [EPR2423(2)] to LRP6
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
Synthetic peptide within Human LRP6 aa 1500-1600. The exact sequence is proprietary.
- WB: HAP1, HeLa, HepG2, 293T, and Jurkat whole cell lysate (ab7899).
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA
Concentration information loading...
PurityProtein A purified
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab134146 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/1000 - 1/10000. Predicted molecular weight: 180 kDa.
1/1000 - 1/10000. Predicted molecular weight: 180 kDa.
FunctionComponent of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Required for posterior patterning of the epiblast during gastrulation.
Tissue specificityWidely co-expressed with LRP5 during embryogenesis and in adult tissues.
Involvement in diseaseDefects in LRP6 are the cause of autosomal dominant coronary artery disease type 2 (ADCAD2) [MIM:610947].
Sequence similaritiesBelongs to the LDLR family.
Contains 4 EGF-like domains.
Contains 3 LDL-receptor class A domains.
Contains 20 LDL-receptor class B repeats.
DomainThe YWTD-EGF-like domains 1 and 2 are required for the interaction with Wnt-frizzled complex. The YWTD-EGF-like domains 3 and 4 are required for the interaction with DKK1.
The PPPSP motifs play a central role in signal transduction by being phosphorylated, leading to activate the Wnt signaling pathway.
modificationsDual phosphorylation of cytoplasmic PPPSP motifs sequentially by GSK3 and CK1 is required for AXIN1-binding, and subsequent stabilization and activation of beta-catenin via preventing GSK3-mediated phosphorylation of beta-catenin. Phosphorylated, in vitro, by GRK5/6 within and outside the PPPSP motifs. Phosphorylation at Ser-1490 by CDK14 during G2/M phase leads to regulation of the Wnt signaling pathway during the cell cycle. Phosphorylation by GSK3B is induced by RPSO1 binding and inhibited by DKK1. Phosphorylated, in vitro, by casein kinase I on Thr-1479.
Undergoes gamma-secretase-dependent regulated intramembrane proteolysis (RIP). The extracellular domain is first released by shedding, and then, through the action of gamma-secretase, the intracellular domain (ICD) is released into the cytoplasm where it is free to bind to GSK3B and to activate canonical Wnt signaling.
Palmitoylation on the two sites near the transmembrane domain leads to release of LRP6 from the endoplasmic reticulum.
Mono-ubiquitinated which retains LRP6 in the endoplasmic reticulum.
N-glycosylation is required for cell surface location.
Cellular localizationMembrane. Endoplasmic reticulum. On Wnt signaling, undergoes a cycle of caveolin- or clathrin-mediated endocytosis and plasma membrane location. Released from the endoplasmic reticulum on palmitoylation. Mono-ubiquitination retains it in the endoplasmic reticulum in the absence of palmitoylation. On Wnt signaling, phosphorylated, aggregates and colocalizes with AXIN1 and GSK3B at the plasma membrane in LRP6-signalsomes. Chaperoned to the plasma membrane by MESD.
- Information by UniProt
- Entrez Gene: 4040 Human
- Entrez Gene: 16974 Mouse
- Omim: 603507 Human
- SwissProt: O75581 Human
- SwissProt: O88572 Mouse
- Unigene: 584775 Human
- Unigene: 658913 Human
- Unigene: 321990 Mouse
- ADCAD2 antibody
- C030016K15Rik antibody
- Cd antibody
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: LRP6 knockout HAP1 cell lysate (20 µg)
Lane 3: HeLa cell lysate (20 µg)
Lane 4: HepG2 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab134146 observed at 220 kDa. Red - loading control, ab18058, observed at 124 kDa.
ab134146 was shown to recognize LRP6 when LRP6 knockout samples were used, along with additional cross-reactive bands. Wild-type and LRP6 knockout samples were subjected to SDS-PAGE. ab134146 and ab18058 (loading control to Vinculin) were diluted 1/10000 and 1/1000 respectively, and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
All lanes : Anti-LRP6 antibody [EPR2423(2)] (ab134146) at 1/1000 dilution
Lane 1 : HeLa cell lysates
Lane 2 : HepG2 cell lysates
Lane 3 : 293T cell lysates
Lane 4 : Jurkat cell lysates
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 180 kDa
Datasheets and documents
ab134146 has been referenced in 23 publications.
- Wu Y et al. LRP6 downregulation promotes cardiomyocyte proliferation and heart regeneration. Cell Res 31:450-462 (2021). PubMed: 32973339
- Miao J et al. Klotho retards renal fibrosis through targeting mitochondrial dysfunction and cellular senescence in renal tubular cells. Physiol Rep 9:e14696 (2021). PubMed: 33463897
- Ni H et al. MiR-95-5p involves in the migration and invasion of trophoblast cells by targeting low density lipoprotein receptor-related protein 6. J Obstet Gynaecol Res 47:184-197 (2021). PubMed: 32924237
- Li DM et al. Hypoxia-Induced miR-137 Inhibition Increased Glioblastoma Multiforme Growth and Chemoresistance Through LRP6. Front Oncol 10:611699 (2020). PubMed: 33718112
- Chehover M et al. Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma. Virchows Arch 477:249-258 (2020). PubMed: 31900634